Point72 Hong Kong’s Inovio Pharmaceuticals INO Stock Holding History

Point72 Hong Kong’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,043	Closed	-$42K	–	841
2022 Q3	$42K	Buy	+2,043	New	+$52.3K	﹤0.01%	1464
2022 Q1	–	Sell	-1,799	Closed	-$108K	–	2076
2021 Q4	$108K	Buy	1,799 +1,108	+160%	+$88.8K	﹤0.01%	1160
2021 Q3	$59K	Buy	+691	New	+$69.3K	﹤0.01%	1482
2021 Q2	–	Sell	-268	Closed	-$30K	–	2120
2021 Q1	$30K	Buy	268 +109	+69%	+$14.3K	﹤0.01%	1393
2020 Q4	$17K	Buy	159 +145	+1,036%	+$19.3K	﹤0.01%	1455
2020 Q3	$2K	Buy	+14	New	+$2.92K	﹤0.01%	1120
2020 Q1	–	Sell	-935	Closed	-$37K	–	1138
2019 Q4	$37K	Buy	+935	New	+$28.1K	0.01%	751
2019 Q3	–	Sell	-349	Closed	-$12K	–	1172
2019 Q2	$12K	Buy	+349	New	+$13.9K	﹤0.01%	844
2018 Q2	–	Sell	-21	Closed	-$1K	–	1028
2018 Q1	$1K	Buy	+21	New	+$1.14K	﹤0.01%	832

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Point72 Hong Kong's INO Position: Q4 2022 in Review

Point72 Hong Kong sold out of Inovio Pharmaceuticals (INO) in Q4 2022, closing a stake of 2,043 shares — an estimated $42K sold.

Point72 Hong Kong first reported a position in INO in Q1 2018 and held it in 9 quarters. The position peaked at $108K in Q4 2021. 183 funds tracked by Wall St. Rank hold INO as of Q4 2022.

Point72 Hong Kong reported no remaining Inovio Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Point72 Hong Kong sold 2,043 Inovio Pharmaceuticals shares in Q4 2022, an estimated $42K.
Point72 Hong Kong first reported a position in Inovio Pharmaceuticals in Q1 2018 and held it in 9 quarters.
Point72 Hong Kong's Inovio Pharmaceuticals position peaked at $108K in Q4 2021.
183 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.